Patent ID: 11903966
Assignee: INTIMA BIOSCIENCE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. A method of treating a cancer in a human subject, the method comprising:
administering to said human subject an immunosuppressive agent; and
administering to said subject a population of ex vivo engineered cancer targeting human primary cells, wherein said population of ex vivo cancer targeting engineered human primary cells comprises CD4+ T cells that comprise:
a) an endonuclease mediated genomic disruption within exon 2 or exon 3 of a cytokine inducible SH2-containing protein gene (CIS-1) sequence, wherein said endonuclease mediated genomic disruption comprises an indel, and wherein said genomic disruption suppresses expression of a protein encoded by the cytokine inducible SH2-containing protein gene (CIS-1); and
b) an exogenous cell surface receptor or functional fragment thereof capable of binding a cell of said cancer, and
wherein said cancer is selected from the group consisting of bladder cancer, bone cancer, brain cancer, esophageal cancer, gastrointestinal cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, anal cancer, rectal cancer, ocular cancer, cancer of the neck, gallbladder cancer, pleural cancer, oral cancer, cancer of the vulva, colon cancer, cervical cancer, fibrosarcoma, kidney cancer, mesothelioma, mastocytoma, nasopharynx cancer, pancreatic cancer, peritoneal cancer, small intestine cancer, stomach cancer, testicular cancer, and thyroid cancer.